News

MIT Technology Review names BenevolentAI as a top 10 breakthrough tech

Today we’re honoured to be named as one of MIT Technology Review’s top 10 breakthrough technologies of 2020.

The prestigious list, curated by MIT Technology Review’s editorial team, is subject to meticulous research and a rigorous process of elimination in order to identify the ten most important technology breakthroughs of the year which are expected to have the biggest impact on human life in the decade ahead.

AI-enabled molecules feature as one of the technologies on the 2020 list, where we’re proud to be recognised for our work in AI-driven chemical design. Our compound design is based on complex multiparametric optimisations set by medicinal chemists working alongside our AI scientists, with a scoring function that factors in all the properties we are seeking to optimise for that molecule.

David Rotman, Editor at Large, MIT Technology on the importance of AI-discovered molecules.:

"The ability of deep learning and other AI tools to find novel molecules with desirable properties will transform drug discovery. It promises to make the development of new medicines far faster and more effective, and is an important new tool in the hunt for better drugs."

Last year, we also released 'GuacaMol', an open-source Python framework that enables the entire research community to access generative chemistry models for benchmarking de novo molecular design.

Drug discovery scientists using our AI platform can select the most promising molecules. They can adapt and optimise compounds using interactive design tools and take them into synthesis and biological testing. Drug discovery scientists apply their knowledge (and bias) but, equally, they can become inspired by the AI and take their design in unexplored directions. Our aim is to empower scientists through the AI platform, believing that the best results come from feeding the interplay between scientists and AI.

The result is that drug discovery scientists can test a more accurate, smaller sample of compounds - cutting the time and cost of designing a drug by years. Our chemical design process is one component of a bigger integrated approach that spans from data collection, target identification up to clinical trials.Designing better medicines using AI and big data. Our team of scientists and AI experts present a ‘behind the scenes’ introduction to show how our latest advancements in machine learning and AI can better understand the underlying causes of diseases, and redefine the way in which new medicines are discovered and brought to patients.

More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022